Page
What are Patient and Family Seminars?
The IMF hosts educational Patient and Family Seminars in cities around the world. At these meetings, patients and their families learn about the latest developments in myeloma from a panel of world-renowned myeloma experts. With the newest information about…
Page
Designed for those seeking support and more information in smaller communities, IMF Myeloma Community Workshops offer families a condensed version of the full Patient & Family Seminar at no charge.
They usually take place on Saturdays from 9 a.m. – 3 p.m.
Lunch and refreshments are…
Author
Dr. Brian G.M. Durie: Pioneer in Myeloma Research and Patient Advocacy Brian G.M. Durie, MD Dr. Brian G.M. Durie (1942-2025), a co-founder of the International Myeloma Foundation, was a Hematologist/Oncologist specializing in multiple myeloma and related disorders at the…
Videos
In this week’s video, Dr. Brian G.M. Durie discusses other options to consider if your doctor recommends a second autologous stem cell transplant.
BOTTOM LINE:
Discuss with your doctor the benefits and side effects of a second transplant as opposed to immune therapies and…
Videos
Selinexor is a novel, oral Selective Inhibitor of Nuclear Export (SINE) compound that blocks exportin 1 (XPO1). Selinexor treatment results in nuclear accumulation and activation of tumor suppressor proteins, inhibition of NF-kB, and translational suppression of several oncoprotein mRNAs (e.g., c-…
Videos
Maintenance therapy has been extensively explored as a strategy for prolonging the duration of disease control and potentially survival following ASCT. To date, only lenalidomide has been approved for this indication. However, lenalidomide maintenance is associated with the development of second…
Videos
Dara, a human IgGκ monoclonal antibody that targets CD38, is approved as monotherapy and in combination with Vd, Rd, and pomalidomide-d for the treatment of relapsed MM and in combination with V, melphalan, and prednisone (VMP) for treatment of ASCT-ineligible ND MM. Addition of dara to these…
Videos
Multiple myeloma (MM) is an incurable plasma cell malignancies despite the advent of numerously new drugs. Survival was poor particularly for high risk patients such as R-ISS stage III. The preliminary data from our center showed that the median PFS after auto-HSCT was 24 months for patients with R…
Videos
Isatuximab (ISA) is an anti-CD38 monoclonal antibody with multiple modes of action for killing tumor cells via direct tumor targeting and immune cell engagement. ISA, combined with bortezomib, has demonstrated strong potentiation in a multiple myeloma (MM) xenograft model (Clin Cancer Res 2014:20:…
Videos
Proteasome inhibitor (PI)-based induction and consolidation proved to be effective in newly diagnosed multiple myeloma (NDMM) patients (pts) eligible for melphalan 200 mg/m2-autologous stem cell transplant (MEL200-ASCT). High response rates have been reported with the second-generation PI…
Videos
Selinexor is a first-in-class Selective Inhibitor of Nuclear Export (SINE) compound that binds and inactivates Exportin 1 (XPO1). Selinexor with low dose dexamethasone (Xd) or in with protesome inhibitors (PIs) or immunomodulatory drugs (IMiDs), has shown anti-MM activity in patients (pts) with…